ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
June 27, 2024 05:00 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
June 26, 2024 05:00 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. SECURES KEY PATENT IN EUROPE FOR HUMAN KLOTHO GENE RNA SLICE VARIANT AND PROTEIN
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
June 12, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
June 05, 2024 08:00 ET
|
PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
Kymanox® Announces Facility Expansion to Enhance CGxP Space and Laboratory Service Offerings
June 03, 2024 10:16 ET
|
Kymanox
King of Prussia, Pennsylvania USA, June 03, 2024 (GLOBE NEWSWIRE) -- Kymanox is pleased to announce the expansion of its device design and testing facility in King of Prussia (KOP), PA, which will...
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 22, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
May 21, 2024 12:35 ET
|
PRISM MarketView
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
Posting of Annual Report & Notice of AGM - Total Voting Rights
May 15, 2024 03:58 ET
|
Biodexa Pharmaceuticals PLC
May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 14, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...